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 A race for RAGE ligands 
 Erwin D.  Schleicher 1 
 In experimental animals a causal involvement of the multiligand 
receptor for advanced glycation end products (RAGE) in the 
development of diabetic vascular complications has been 
demonstrated. However, the nature of RAGE ligands present in patients 
with diabetic nephropathy has not yet been defined; this leaves open 
the relevance of the RAGE system to the human disease. 
 Kidney International (2010)  78, 234 – 236.  doi: 10.1038/ki.2010.146 
 Th e glycated hemoglobin HbA1c is now 
widely accepted for assessment of the meta-
bolic control of diabetic patients. Since 
large epidemiological studies (the Diabetes 
Control and Complications Trial and the 
UK Prospective Diabetes Study) clearly 
indicate that diabetic microvascular, par-
ticularly retinal and renal, complications 
are associated with glycemic control 
assessed by HbA1c, therapeutic goals have 
been introduced in the respective guide-
lines. The importance of blood glucose 
levels for the development of late diabetic 
complications has long been known and 
implies that chronically elevated glucose 
levels are deleterious to the vascular sys-
tem. Several fi ndings argue against a direct 
toxic eff ect of increased glucose concentra-
tions: (1) blood with the same degree of 
hyperglycemia is circulating through all 
organs and tissues of a given diabetic 
patient, but the kidneys, retinas, or nerves 
are diff erently aff ected intra- and interin-
dividually; (2) while some patients with 
poor metabolic control, that is, substantial 
hyperglycemia, have few, if any, microvas-
cular complications, other patients with 
appropriate metabolic control experience 
fast and widespread microvascular lesions; 
(3) aff ected tissues appear to have a  ‘ glyc-
emic memory ’ ; and (4) in nondiabetic sub-
jects, HbA1c is more strongly associated with 
risks of cardiovascular disease and death 
from any cause as compared with fasting 
glucose. 1 Furthermore, the animal kingdom 
teaches us that lifelong glucose levels above 
200  mg / dl, for example in birds, are not neces-
sarily accompanied by microvascular 
lesions — even in long-lived parrots. Together 
these arguments indicate that elevated glu-
cose  per se may not be the toxic agent causing 
the diabetes-specifi c vascular lesions. 
 Th e fi nding that not only HbA1c but also 
other proteins in the human body are sub-
ject to glycation has raised the possibility 
that hyperglycemia via glycation of proteins 
may cause the deleterious eff ects in poorly 
controlled diabetic patients. Indeed, in dia-
betic subjects, elevated glycation was found 
in long-lived, particularly extracellular, pro-
teins of aff ected organs and tissues such as 
glomeruli, nerves, and aortas, and also in 
lungs and tendons. Vlassara  et al. 2 recog-
nized that glycated proteins are not stable 
over time and thus form advanced glycation 
end products (AGEs), a still poorly defi ned, 
heterogeneous group of protein modifi ca-
tions. Meanwhile, the oxidative formation 
of  N -carboxymethyl-lysine (CML) from 
protein-bound glycated lysines has been 
shown to be a major AGE in vascular lesions 
that is increased in diabetic patients. 3 
 However, the presence of AGE did not 
explain the pathogenesis of hyperglyc-
emia-induced vascular lesions. A major 
step forward was the identification of 
a cell-surface receptor for AGEs (RAGE) 
by Neeper  et al. 4 Later on, a soluble 
form of RAGE (sRAGE) was found in 
plasma of experimental animals and dia-
betic patients. Subsequent characteriza-
tion revealed RAGE as a multiligand 
pattern recognition receptor of the immu-
noglobulin superfamily. RAGE does not 
promote the uptake and removal of lig-
ands, but the RAGE – ligand interaction 
induces a proinfl ammatory and proco-
agulant state. Ligand engagement of 
RAGE activates the nuclear factor-  B 
(NF-  B) and Egr-1 signaling pathways, 
both involved in acute cellular stress 
responses. Activation of these pathways, 
which includes the stimulation of reactive 
oxygen species, leads to enhanced expres-
sion of proinfl ammatory cytokines such 
as interleukins and tumor necrosis factor. 
Prolonged activation of RAGE results in 
sustained activation of NF-  B through  de 
novo synthesis of RelA / p65, generating an 
increasing pool of transcriptionally active 
NF-  B, which can counteract the negative 
autoregulatory loops. By this mechanism, 
RAGE represents a master switch convert-
ing a transient proinfl ammatory response 
into a sustained cellular dysfunction. 5 
 Although fi rst characterized as a recep-
tor for AGEs, subsequent characterization 
of endogenous binding partners showed 
that RAGE also transduces signals by pro-
teins that are secreted or released from 
cells activated by infl ammatory stimuli. 5 
Collectively, these molecules warn the 
tissue of acute danger and have therefore 
been called danger-associated molecular 
patterns (DAMPs). These endogenous 
binding partners include high-mobility 
group box 1 (HMGB1), members of the 
S100 / calgranulin family,   2 -integrin Mac, 
amyloid-  peptide, and   -sheet fi brils. 
S100 / calgranulins are a family of small 
Ca-binding proteins with a molecular 
weight of approximately 10.5  kDa that 
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have been implicated in the pathogenesis 
of proinfl ammatory pathways. S100A8 / A9 
and S100A12 (EN-RAGE) bind to RAGE 
and activate intracellular signaling cas-
cades. 6 HMGB1, a non-histone DNA-
binding protein with a molecular weight 
of 30  kDa, is released from necrotic but 
not apoptotic cells. Th e function of both 
proteins is not entirely clear, but they may 
have a general role in homeostasis of nor-
mal tissue, since their tissue and plasma 
levels are increased in very diff erent dis-
eases, such as diabetes, atherosclerosis, 
infl ammatory disease, Alzheimer ’ s dis-
ease, and all carcinomas studied to date. 7 
 Th e physiological role of RAGE in dif-
ferent diseases has been studied with the 
use of RAGE-defi cient animals. In these 
animals, early mesangial expansion, albu-
minuria, and also cortex levels of vascular 
endothelial growth factor and transform-
ing growth factor-  transcripts were 
reduced in comparison with control ani-
mals. 8 Similar results were obtained by 
long-term administration of soluble RAGE 
(sRAGE). Th e involvement of RAGE in the 
development of diabetic nephropathy was 
further supported by the finding that 
transgenic mice overexpressing RAGE 
exhibited exacerbation of the indices of 
nephropathy, and this was prevented by 
the inhibition of AGE formation. More-
over, the application of small molecules 
interrupting the AGE – RAGE axis reduces 
diabetes-induced structural and functional 
changes. So far, studies with rodents sup-
port a causal role for RAGE in the patho-
genesis of diabetic nephropathy. However, 
the role of RAGE in human diabetic neph-
ropathy is less well documented. In the 
human diabetic kidney, RAGE is particu-
larly expressed in podocytes and in vascu-
lar cells, and possible ligands and induced 
cytokines are found to be colocalized, but 
the (patho)physiological RAGE ligand 
remains to be characterized. 9 
 Penfold  et al. 10 (this issue) studied 
normo-, micro-, and macroalbuminuric 
diabetic patients to examine the pathogenic 
potential of circulating RAGE ligands 
present in type 2 diabetes. First they deter-
mined the serum levels of potential RAGE 
ligands by enzyme-linked immunosorbent 
assay (ELISA) and found that sRAGE and 
S100A8 / A9 protein concentrations were 
not diff erent between all groups, while the 
HMGB1 level was decreased in all diabetic 
patients as compared with control subjects. 
As expected, and confirming previous 
results, CML-modifi ed plasma proteins 
were elevated in all diabetic patients, but no 
change in circulating sRAGE concentra-
tions was observed. When serum proteins 
were separated into fractions of   <  30, 
30 – 50, and >50  kDa, only the high-molecular-
weight fractions contained the respective 
ligand, whereas little or no ligand was 
found in the low-molecular-weight frac-
tions. Th is fi nding was confi rmed by elec-
trophoretic separation on non-reducing 
gels. Reducing conditions revealed HMGB1 
protein complexes of 40 and 70  kDa, and 
immunoblotting showed that HMGB1 
protein complexes contained IgG. Specifi c 
ligand binding to RAGE was found only in 
the high-molecular-weight fraction. Fur-
thermore, these fractions were biologically 
active in inducing RAGE expression, vas-
cular endothelial growth factor expression, 
and protein kinase C-  phosphorylation. 
 Th e authors interpret their fi ndings with 
appropriate caution given their relatively 
small sample size (20 patients per group) and 
some unexplained fi ndings that may have 
been caused by the poorly defi ned nature of 
the ligands. Th e major importance of this 
study is the finding that the biologically 
active RAGE ligands present in the circula-
tion of diabetic patients are aggregates 
and may be in complex with other proteins 
( Figure 1 ). It may be speculated that these 
aggregates bind with higher affi  nity and / or 
induce RAGE receptor dimerization leading 
to enhanced signal transduction. Th e results 
also indicate the problem with using ELISA 
technique for quantifi cation of a specifi c lig-
and. With this analytical technique, the con-
centration of circulating HMGB1 was found 
to be decreased in diabetic patients with 
macroalbuminuria, whereas with separation 
of reduced serum by SDS gel electrophoresis, 
increased HMGB1 was found for this stage 
of diabetic nephropathy. Th ese observations 
may indicate that the polyvalent nature of the 
RAGE ligands may cause problems in detec-
tion with antibodies, because the respective 
epitope may be masked. 
 From this study, one may expect that the 
circulating polyvalent RAGE ligands that 
are modifi ed by, for instance, CML and / or 
complexed with other proteins (IgG) or 
DNA may bind to diff erent receptors with 
affi  nities depending on the degree of modi-
fi cation and complexation, thus causing 
diff erent biological eff ects. Furthermore, it 
may well be that the binding, stimulation, 
and biological eff ects of RAGE are caused 
by other modifi cations or complex partners 
not specifi cally tested in this study, since 
addition of CML antibody prevents the 
biological eff ect only in part. 11 Th erefore, 











 Figure 1  |  Ligands binding to RAGE and activating intracellular signaling cascades. Numerous 
ligands for the pattern recognition receptor RAGE have been identified. These include high-mobility 
group box 1 (HMGB1), members of the S100 / calgranulin family,   2 -integrin Mac, amyloid-  
peptide, and   -sheet fibrils. Engagement of the ligand with RAGE leads to activation of nuclear 
factor-  B (NF-  B) and other signaling pathways with subsequent expression of inflammatory 
cytokines. Furthermore, activation of RAGE converts a transient stimulus into a sustained cellular 
response. From the study by Penfold  et al. , 10 it appears that RAGE ligands in human plasma 
are present in aggregates and complexes with other partners. It may be speculated that these 
aggregates bind with higher affinity and / or induce RAGE receptor dimerization, leading to 
enhanced signal transduction. X indicates an heterogenous binding partner like IgG. 
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circulating RAGE ligands is necessary to 
establish a reliable tool for the assessment 
of the activity of the RAGE system in human 
subjects. Th e study may also be relevant to 
the role of RAGE and its circulating ligands 
in other diseases with an activated AGE –
 RAGE axis, such as carcinomas, Alzhei mer ’ s 
disease, and atherosclerosis. Th ese aggregates 
may be general phenomena, and the investi-
gation of plasma from patients suffering 
from these diseases may help to clarify the 
role of the endo genous ligands. 
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 Maximal  ‘ CD80-uria ’ with 
minimal change 
 Andreas D.  Kistler 1 and  Jochen  Reiser 1 
 Differentiation between minimal-change disease and focal segmental 
glomerulosclerosis remains challenging, particularly at early stages in 
children and adults. Garin  et al. identify urinary CD80 excretion levels as a 
potential marker to differentiate the former entity from the latter. Thus, 
CD80 expression on podocytes, which was initially described in mouse 
models of foot process effacement and human lupus nephritis, is now 
brought toward clinical application for use as a diagnostic biomarker. 
 Kidney International (2010)  78, 236 – 238.  doi: 10.1038/ki.2010.148 
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syndrome. Th e disease is ultrastructurally 
characterized by podocyte foot process 
effacement without light-microscopic 
signs of glomerulosclerosis and interstitial 
fibrosis. Some patients who on initial 
evaluation are diagnosed as having MCD 
later develop focal segmental glomerulo-
sclerosis (FSGS), a process of progressive 
glomerular scarring. It is an ongoing 
debate whether MCD and FSGS represent 
diff erent stages of one common patho-
physiological process or whether they are 
diff erent disease entities, with some FSGS 
patients initially misdiagnosed as having 
MCD because of biopsy sampling error. 
 Garin  et al. 1 (this issue) now demon-
strate that urine levels of CD80 may be 
used to distinguish MCD from FSGS. 
Th ey have previously shown signifi cantly 
elevated urinary CD80 levels in pediatric 
patients with MCD during relapse as com-
pared with MCD in remission, healthy 
controls, and a small number of patients 
with other glomerular diseases. 2 They 
now extend their previous studies by com-
paring MCD patients with a group of 
22 FSGS patients. Th ey were able to show 
that the elevated urinary CD80 levels are 
specifi c to MCD as compared with FSGS 
patients with similar degrees of proteinu-
ria. Urinary CD80 levels had a high dis-
criminatory value for the two entities, with 
an area under the receiver operating char-
acteristic curve of 0.99. These findings 
were corroborated with immunofl uores-
cent stainings of biopsy samples showing 
high expression of CD80 in glomeruli of 
MCD patients in relapse but not of MCD 
patients in remission or of FSGS patients. 
 CD80 — also termed B7-1 — is a trans-
membrane protein expressed on the sur-
face of B cells and other antigen-presenting 
cells, where it serves as a costimulatory 
signal for T cells through binding to its 
receptors CD28 and CTLA-4. Beyond its 
function as a costimulatory molecule, a 
novel role for CD80 expressed on podo-
cytes was recently found. 3 CD80 is upreg-
ulated in at least two genetic mouse 
models of glomerular disease, the integrin 
  3   −  /  −   and the nephrin   −  /  −   mouse. In 
wild-type mice, podocyte expression of 
CD80 can be induced by the endotoxin 
lipopolysaccharide (LPS) through toll-
like receptor 4 (TLR-4) activation. LPS 
injection leads to transient podocyte foot 
pro cess effacement and proteinuria 
in mice, an eff ect that is independent of 
lymphocytes, as it also occurs in SCID 
mice that are devoid of lymphocytes. 
CD80-defi cient mice are protected from 
LPS-mediated podocyte injury. Another 
way to induce CD80 expression in podo-
cytes is treatment with the antibiotic 
puromycin aminonucleoside. Thus, 
induction of CD80 is an event common 
 Minimal-change disease (MCD) is 
the leading cause of childhood nephrotic 
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